Eicosanoids represent a family of active biolipids derived from arachidonic acid primarily
through the action of cytosolic phospholipase A2-α. Three major downstream pathways …

The epithelial‐to‐mesenchymal transition (EMT) is a developmental programme that
regulates embryonic morphogenesis and involves significant morphological and molecular …

The mammalian target of rapamycin (mTOR) signaling pathway is upregulated in the
pathogenesis of many cancers. Arachidonic acid (AA) and its metabolites play critical role in …

BACKGROUND Previous studies have shown that COX‐2 inhibitors inhibit cancer cell
proliferation. However, the molecular mechanism remains elusive. METHODS Prostate …

Eicosanoids are bioactive lipid mediators derived from arachidonic acid1 (AA), which is
released by cytosolic phospholipase A2 (cPLA2). AA is metabolized through three major …

A series of novel anticancer agents were designed and synthesized based on coupling of
different nonsteroidal anti-inflammatory drugs (NSAIDs) with the epidermal growth-factor …

Clinical trials that include integral biomarkers to determine eligibility, assign treatment, or
assess outcome must employ robust assays to measure the molecular analyte of interest …

Background Eicosanoids as inflammatory mediators take part in the regulation of disease
progression. However, the application of serum eicosanoid in disease progression …

Levels of cyclooxygenase (COX)-2 and its metabolite prostaglandin E2 (PGE2) are
frequently increased in colon cancer and other cancers including lung cancer. Non-steroidal …

Approximately one third of patients with non-small cell lung cancer have unresectable stage
IIIA or stage IIIB disease; combined cytotoxic chemotherapy and radiation therapy delivered …